PD-1 inhibitor and CTLA-4 inhibitor combination

This page covers all PD-1 inhibitor and CTLA-4 inhibitor combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PD-1 and CTLA-4.

Targets

PD-1 and CTLA-4

Phase 3 pipeline (1)

• Adjuvant Nivolumab and Ipilimumab · Universitätsklinikum Hamburg-Eppendorf · Oncology
  Nivolumab and ipilimumab together block immune checkpoints (PD-1 and CTLA-4) to enhance anti-tumor T-cell responses in adjuvant settings.